Keyword: American Society of Hematology
Scientists running the first trial of CRISPR-edited cells to fight cancer are reporting that the therapy has been well tolerated by three patients.
The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Bluebird Bio has been singing the praises of two new therapies at ASH, but investors don’t seem to be fully on board with the program.
At ASH, Fate will present preclinical data on three off-the-shelf, cancer-fighting cell therapies made from stem cells.
Bluebird Bio and Celgene built on impressive early responses in multiple myeloma, with their CAR-T therapy extending PFS to 11.8 months in phase 1.
At the annual ASH meeting, oncologists at the Dana-Farber Cancer Institute demonstrated how simple blood tests may hold promise for managing multiple myeloma.
A set of researchers at the Fred Hutchinson Cancer Research Center in Seattle who are partially funded by Juno are investigating methods for fine-tuning CAR-T treatments—and they presented early signs of success.
One of the most active research endeavors in immuno-oncology involves engineering human viruses into weapons that can fight cancer. Now a group of scientists at the University of Parma in Italy is looking to another source of potentially potent cancer-killing viruses: cows.